Sutro Biopharma Inc (NAS:STRO)

$ 3.71 -0.05 (-1.33%) Market Cap: 303.46 Mil Enterprise Value: 18.31 Mil PE Ratio: 0 PB Ratio: 2.36 GF Score: 55/100

Sutro Biopharma Inc Luvelta Investor Webcast Transcript
Jan 04, 2024
Sutro Biopharma Inc at Citi BioPharma Conference Transcript
Sep 06, 2023
Sutro Biopharma Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Sutro Biopharma Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Sutro Biopharma Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Sutro Biopharma Inc STRO-002 Update Transcript
Jan 09, 2023
Sutro Biopharma Inc at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022
Sutro Biopharma Inc at Wells Fargo Healthcare Conference Transcript
Sep 09, 2022
Sutro Biopharma Inc at Wedbush PacGrow Healthcare Conference- Panel Transcript
Aug 10, 2022
Sutro Biopharma Inc Deep Dive Research Forum: Next-Gen Innovations in ADCs Transcript
Jul 20, 2022
Sutro Biopharma Inc at JMP Securities Life Sciences Conference (Virtual) Transcript
Jun 16, 2022
Sutro Biopharma Inc at Needham Healthcare Conference Transcript
Apr 14, 2022
Sutro Biopharma Inc to Discuss Interim Data on the STRO-002 Phase 1 Dose-Expansion Call Transcript
Jan 05, 2022
Sutro Biopharma Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Sutro Biopharma Inc - KOL Discussion Of STRO-002 Data Transcript
Dec 03, 2020
Sutro Biopharma Inc Clinical Data Release and Poster Presentation at the 2020 AACR Virtual Annual Meeting Transcript
Apr 27, 2020

Sutro Biopharma Inc Luvelta Investor Webcast Transcript

Jan 04, 2024 / 09:30PM GMT

Release Date Price: $4.44

Transcript 8-K

Operator

Good day and thank you for standing by, and welcome to the Sutro Biopharma Luvelta Forum webcast and conference call. (Operator Instructions) Again, please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Bill Newell, Chief Executive Officer of Sutro Biopharma. Please go ahead.

William Newell

Sutro Biopharma Inc - Chief Executive Officer, Director

Thank you, Jonathan, and welcome to everybody who is joining us for today's Luvelta Forum. We decided to call this event a forum because for the first time, we will be presenting a comprehensive overview of the clinical and preclinical data in both solid tumors and hematologic malignancies that illustrates the broad therapeutic potential of our lead molecule, luveltamab tazevibulin or as we call it, luvelta.

Today, for the first time, we'll be presenting aggregated response data from approximately 100 treated ovarian cancer patients. We will also be presenting constant durability data for an aggregated 43 ovarian cancer patients,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.